Satellos Bioscience to Join Guggenheim Biotech Summit

Rhea-AI Filing Summary

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York City on February 12, 2026, at 10 a.m. ET.

The session will be available via live webcast on Satellos’ investor relations website, with a replay offered afterward. Company leaders will also hold one-on-one meetings with investors. Satellos highlights its lead oral small-molecule candidate SAT-3247, which targets AAK1 and is in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Satellos Bioscience (MSCLF) announce in this 6-K filing?

Satellos Bioscience announced that its management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026. The company will also host one-on-one investor meetings and provide webcast and replay access through its investor relations website.

When and where will Satellos’ Guggenheim Biotech Summit fireside chat take place?

Satellos’ fireside chat will take place in New York City on February 12, 2026, at 10 a.m. Eastern Time. The event is part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 and will feature company management discussing the business.

How can investors access Satellos Bioscience’s Guggenheim Summit presentation?

Investors can access Satellos’ fireside chat via a live webcast on the Events and Presentations page in the Investors section of the company’s website. A replay will be available after the event for those unable to watch the live session in real time.

What is Satellos Bioscience’s lead drug candidate SAT-3247?

SAT-3247 is an orally administered, small molecule drug developed by Satellos to help restore natural muscle repair and regeneration. It targets the AAK1 protein to restore disrupted muscle stem cell signaling and is in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy.

Which diseases is Satellos Bioscience initially targeting with SAT-3247?

Satellos is initially developing SAT-3247 as a potential disease-modifying treatment for Duchenne muscular dystrophy. The company is also exploring additional muscle diseases or injury conditions where restoring muscle repair and regeneration could offer therapeutic benefit and create future clinical development opportunities.

How can investors and media contact Satellos Bioscience for more information?

Investors can contact Satellos by emailing CFO Liz Williams at ir@satellos.com for inquiries or meetings. Media inquiries are directed to Emily Williams, Senior Director of Communications, at media@satellos.com, providing dedicated channels for financial and press-related questions about the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 07:15 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

(Commission File No. 001-43107)

SATELLOS BIOSCIENCE INC.

(Translation of registrant’s name into English)

Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800

Toronto, Ontario, ON M5J 2J3

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ¨               Form 40-F x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ¨

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit		Description
99.1		News Release dated February 10, 2026. Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Satellos Bioscience Inc.

	By:	/s/ Elizabeth Williams, CPA, CA
	Name:	Elizabeth Williams, CPA, CA
	Title:	Chief Financial Officer

Date: February 10, 2026

Exhibit 99.1

 

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

TORONTO, Feb. 10, 2026 (BUSINESS WIRE) — Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in NYC on Thursday, Feb. 12, 2026, at 10 a.m. ET.

The fireside chat will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website. A replay will be available following the event.

Members of the Satellos leadership team will also be available for one-on-one investor meetings during the conference. Investors interested in scheduling a meeting may contact their Guggenheim representative or reach out directly to Satellos at ir@satellos.com.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.

CONTACTS

Investors: Liz Williams, CFO, ir@satellos.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 4.3 KB